Fosun Pharma (600196.SH) announced that its subsidiary Shanghai Henlius Biotech Co., Ltd. and its subsidiary Henlius have recently received approval from the National Medical Products Administration for conducting clinical trials of HLX17 (recombinant anti-PD-1 humanized monoclonal antibody injection) for the treatment of melanoma, non-small cell lung cancer, esophageal cancer, head and neck squamous cell carcinoma, colorectal cancer, hepatocellular carcinoma, triple-negative breast cancer, and tumors with microsatellite instability or mismatch repair gene deficiency.
As of the date of the announcement, the approved monoclonal antibody pembrolizumab in China is manufactured by Merck Pharmaceuticals Co., Ltd. According to the latest IQVIA CHPA data, the sales of pembrolizumab in China in 2023 amounted to approximately RMB 1.425 billion.